ISIN:FR0012333284

DGAP-News: Abivax provides an update on the ABX464 clinical data and development strategy in ulcerative colitis

Tuesday, September 14, 2021 - 5:09pm

At present, Abivax is preparing the upcoming consultations with the key regulatory agencies to discuss the phase 3 program in UC and the overall clinical development strategy of ABX464.

Key Points: 
  • At present, Abivax is preparing the upcoming consultations with the key regulatory agencies to discuss the phase 3 program in UC and the overall clinical development strategy of ABX464.
  • The total market opportunity for ABX464 is USD 6.0B annually, based on 2020 pharmaceutical sales estimates for ulcerative colitis in these countries.
  • Abivax will provide the half-year 2021 financial results as well as an operational update before the end of next week.
  • Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe chronic inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.

DGAP-News: Abivax receives approval for ABX464 phase 1 study in Japanese subjects for subsequent inclusion of Japan into the global phase 3 program in ulcerative colitis

Wednesday, August 18, 2021 - 12:51pm

This trial is required as part of the common clinical development plan to confirm the pharmacokinetic (PK) profile of ABX464 in Japanese subjects.

Key Points: 
  • This trial is required as part of the common clinical development plan to confirm the pharmacokinetic (PK) profile of ABX464 in Japanese subjects.
  • Given positive results of this phase 1 study, Abivax will be able to include Japanese patients in its global phase 3 clinical development program of ABX464 for the treatment of ulcerative colitis.
  • Prof. Hartmut J. Ehrlich, M.D., CEO of Abivax said: "The approval of our phase 1 study by the Japanese regulators is another important milestone as we are executing on our ABX464 global development strategy.
  • Once the pharmacokinetics as well as safety and tolerability of ABX464 have been confirmed in the Japanese population, we will be able to subsequently expand our phase 3 clinical program to Japan.

Abivax publishes a prospectus in the context of its capital increase and bonds offering

Saturday, July 24, 2021 - 2:11am

The issuer is solely responsible for the content of this announcement.

Key Points: 
  • The issuer is solely responsible for the content of this announcement.
  • Abivax, a clinical stage biotechnology company, is developing novel therapies that modulate the physiological inflammation and immunological pathways to treat patients with chronic inflammatory diseases, viral infections, and cancer.
  • Abivax is listed on Euronext compartment B (ISIN: FR0012333284 - Mnmo: ABVX).
  • Based in Paris and Montpellier, Abivax has two drug candidates in clinical development, ABX464 to treat severe inflammatory diseases, and ABX196 to treat hepatocellular carcinoma.